My watch list

Alatrofloxacin


Alatrofloxacin
Systematic (IUPAC) name
7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-aminopropanoyl]amino}- 1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]- 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine- 3-carboxylic acid
Identifiers
CAS number	157182-32-6 157605-25-9 (mesylate)
ATC code	?
PubChem	5489474
Chemical data
Formula	C₂₆H₂₅F₃N₆O₅
Mol. mass	558.509 g/mol
Pharmacokinetic data
Bioavailability	N/A
Protein binding	76% (trovafloxacin)
Metabolism	Quickly hydrolyzed to trovafloxacin
Half life	9 to 12 hours (trovafloxacin)
Excretion	Fecal and renal (trovafloxacin)
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	Withdrawn
Routes	Intravenous

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.^[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.^[2]^[3]

Additional recommended knowledge

What is the Sensitivity of my Balance?

What is the Correct Way to Check Repeatability in Balances?

Daily Visual Balance Check

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

References

^ PubChem CID 5489474.
^ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
^ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.